Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

C R BARD INC (BCR)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
324.54(c) 327(c) 327.3(c) 330.16(c) 329.61 Last
280 422 587 022 450 750 425 797 84 681 Volume
+0.39% +0.76% +0.09% +0.87% -0.17% Change
More quotes
Financials ($)
Sales 2017 3 931 M
EBIT 2017 1 180 M
Net income 2017 805 M
Finance 2017 70,2 M
Yield 2017 0,32%
Sales 2018 4 163 M
EBIT 2018 1 287 M
Net income 2018 902 M
Finance 2018 34,0 M
Yield 2018 0,34%
P/E ratio 2017 32,52
P/E ratio 2018 28,21
EV / Sales2017 6,09x
EV / Sales2018 5,76x
Capitalization 23 993 M
More Financials
Company
C.R. Bard, Inc. designs, develops, manufactures, distributes and markets medical technologies in the fields of vascular, urology, oncology and surgical specialty products.It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site... 
More about the company
Surperformance© ratings of C R Bard Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on C R BARD INC
10/18 C R BARD : BD Statement On European Commission Conditional Clearance Of Bard Acq..
10/14 C R BARD : Judicial Panel on Multidistrict Litigation Issues Order on C.R. Bard
10/12 C R BARD : Stock Performance Review on Medical Supplies Industry -- Microbot Med..
10/11 C R BARD : Bard Declares Quarterly Dividend
09/28 C R BARD : Becton Dickinson offers EU concessions over $24 billion Bard deal
08/31 C R BARD : Receives FDA Premarket Approval of the LUTONIX 035 Drug Coated Balloo..
08/28 C R BARD : Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Ballo..
08/22 EARNINGS REVIEW AND FREE RESEARCH RE : Becton, Dickinson and Co.’s Q3 Adju..
08/11 INSIDER TRADING ACTIVITY C.R. BARD, : BCR) – Insider Sold 23,687 shares o..
08/10 BACTIGUARD : Interim report for Q2 2017
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04:18p Smith & Nephew to buy Rotation Medical for up to $210 million
10/16DJDentsply General Counsel Exits, Marking Fourth Resignation in Recent Weeks --..
10/16DJDentsply Sirona General Counsel Exits, Marking Fourth Resignation in Recent W..
10/13 Toshiba discussing joint investment in chips with Western Digital
10/11 Mondi drags on FTSE, Provident Financial sinks
More sector news : Medical Equipment, Supplies & Distribution - NEC
4-Traders Strategies on C R BARD INC 
C.R. BARD - 2013
Still an upward potential
BUY
More Strategies
Latest Tweets
10/21C.R. Bard, Inc. $BCR Shares Sold by Raymond James Financial Services Advisors.. 
10/21C.R. Bard, Inc. $BCR Expected to Post Quarterly Sales of $992.30 Million  
10/20Harvey Investment Co. LLC Sells 1,063 Shares of C.R. Bard, Inc. $BCR  
10/20Frank Lupisella, Jr. Sells 9,173 Shares of C.R. Bard, Inc. $BCR Stock  
10/20$BCR ALERT: New C. R. Bard, Inc. SEC Filing From our Stock News Alerts App 
More tweets
Qtime:178
News from SeekingAlpha
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/11 C. R. Bard declares $0.26 dividend
10/09 First meeting of new FDA advisory committee this week
09/26 Most Overbought And Oversold S&P Stocks
09/04 Dividend Income Update August 2017
Chart C R BARD INC
Duration : Period :
C R Bard Inc Technical Analysis Chart | BCR | US0673831097 | 4-Traders
Technical analysis trends C R BARD INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 303 $
Spread / Average Target -8,2%
EPS Revisions
Managers
NameTitle
Timothy M. Ring Chairman & Chief Executive Officer
John H. Weiland President, Chief Operating Officer & Director
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC46.96%23 993
MEDTRONIC PLC9.98%106 119
BAXTER INTERNATIONAL43.41%34 648
ZIMMER BIOMET HOLDINGS INC18.56%24 739
HOYA CORPORATION29.06%21 802
ALIGN TECHNOLOGY, INC.108.97%16 101